大洋洲 · 区域市场 · Stockhead
Healthcare Quarterly Wrap: These biotechs are pushing for Phase 3 progress
Alterity has FDA agreement on ATH434’s pivotal trial design, while Recce has revised its Australian study and signed an Australia ... Read More The post Healthcare Quarterly Wrap:…
在 Stockhead 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (stockhead.com.au)
